Ingram Micro Issues Statement Regarding Cybersecurity Incident 
Texas Flood Victims Offered 30 Days Free Storage at 37 U-Haul Centers 
DDC Developments Announces 200% Surge in Demand and Launches National Expansion with New Manufacturing Facility 
Law Offices of Robert Gregg Celebrates 33+ Years of Legal Excellence 
Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation Esker To Pay €0.75 per Share As Dividend for 2022, Up 25%, Affirming Growth Momentum for 2023
Long-standing shareholders to receive a 10% bonus LYON, France & MIDDLETON, Wis.–(BUSINESS WIRE)–Esker, a global…
KBRA Releases Research – CMBS Loan Performance Trends: June 2023
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA releases a report on U.S. commercial mortgage-backed securities (CMBS) loan performance trends…
LifeArc strengthens Board of Trustees with new appointments
LifeArc strengthens Board of Trustees with new appointments 27 June 2023: LifeArc, the self-funded medical…
LifeArc strengthens Board of Trustees with new appointments
LifeArc strengthens Board of Trustees with new appointments 27 June 2023: LifeArc, the self-funded medical…
GRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio
– U.S. patent issuance for lead program, GRI-0621, in development for the treatment of idiopathic…
GRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio
– U.S. patent issuance for lead program, GRI-0621, in development for the treatment of idiopathic…
AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
Ampligen has shown therapeutic synergies with checkpoint inhibitors, potentially increasing survival rates and efficacy Patient…
AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
Ampligen has shown therapeutic synergies with checkpoint inhibitors, potentially increasing survival rates and efficacy Patient…
Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate
Booster study successfully met its primary objective, demonstrating non-inferiority to mRNA-vaccine Regulatory pathway will depend…
Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate
Booster study successfully met its primary objective, demonstrating non-inferiority to mRNA-vaccine Regulatory pathway will depend…
Shareholders Approve all Board Proposals at Today’s Annual General Meeting
Pratteln, Switzerland, June 27, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders approved all…
Shareholders Approve all Board Proposals at Today’s Annual General Meeting
Pratteln, Switzerland, June 27, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders approved all…
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701
BOSTON, June 27, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare…
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701
BOSTON, June 27, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare…
Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium
ART26.12, a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor, Shows Favorable Results in Studies…
Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium
ART26.12, a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor, Shows Favorable Results in Studies…
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million
YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million
YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights
MDNA11 demonstrates durable single-agent activity in forth-line metastatic pancreatic cancer patient with a partial response…
Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights
MDNA11 demonstrates durable single-agent activity in forth-line metastatic pancreatic cancer patient with a partial response…